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Pharmacokinetic Targets for Therapeutic Drug 
Monitoring of Small Molecule Kinase Inhibitors 
in Pediatric Oncology
Julie M. Janssen1,*, Thomas P. C. Dorlo1, Neeltje Steeghs2, Jos H. Beijnen1,3, Lidwien M. Hanff4,  
Natasha K. A. van Eijkelenburg4, Jasper van der Lugt4, C. Michel Zwaan4,5 and Alwin D. R. Huitema1,6
In recent years new targeted small molecule kinase inhibitors have become available for pediatric patients with 
cancer. Relationships between drug exposure and treatment response have been established for several of these 
drugs in adults. Following these exposure–response relationships, pharmacokinetic (PK) target minimum plasma 
rug concentration at the end of a dosing interval (Cmin) values to guide therapeutic drug monitoring (TDM) in adults 
have been proposed. Despite the fact that variability in PK may be even larger in pediatric patients, TDM is only 
sparsely applied in pediatric oncology. Based on knowledge of the PK, mechanism of action, molecular driver, and 
pathophysiology of the disease, we bridge available data on the exposure–efficacy relationship from adults to children 
and propose target Cmin values to guide TDM for the pediatric population. Dose adjustments in individual pediatric 
patients can be based on these targets. Nevertheless, further research should be performed to validate these targets.
The number of targeted small molecule kinase inhibitors (KIs) 
approved for the treatment of cancer in adults is rapidly expand-
ing, which has led to increased pediatric treatment options as well. 
Over the past two decades, efforts have been made by clinicians 
and regulatory agencies to increase the incorporation of pediat-
ric research into the registration processes.1 This includes the re-
quirement to agree on a pediatric investigational plan before an 
adult marketing access can be obtained in Europe and several ex-
trapolation approaches that use existing information in the adult 
population to accelerate pediatric development.2,3 However, since 
the type of adult cancer for which a drug is approved often does 
not occur in children, waivers are frequently granted for pediat-
ric development, and it has been argued that in fact a target-based 
waiver system would be more appropriate.4
Up to 2016, only two KIs had been approved by the US Food 
and Drug Administration (FDA) for the treatment of childhood 
cancers: Imatinib for Philadelphia chromosome-positive (Ph+) 
chronic myeloid leukemia (CML) and everolimus for subependy-
mal giant-cell astrocytoma.2,3 Only recently, dasatinib, nilotinib, 
and larotrectinib have been approved by the FDA for the treatment 
of pediatric cancers.5,6 To incentivize the pediatric development of 
approved adult KIs in oncology, the European Medicines Agency 
(EMA) and FDA both provide guidance for pediatric study plans 
based on expression of molecular targets.
Large pharmacokinetic (PK) variability has been observed for 
almost all of the KIs approved in adults. A broad range of factors, 
such as genetics, food intake, drug formulation, and use of con-
comitant medication may influence the absorption, distribution, 
metabolism, and excretion of drugs.7–9 As a result of changing 
body composition, body size, maturation of organ functions, and 
treatment compliance, additional dimensions of variability in PK 
are present in pediatric patients.10 Resulting variability in exposure 
may, especially in children, lead to suboptimal efficacy or substan-
tial toxicity caused by low or high drug exposure, respectively. 
Hence, by using exposure–efficacy relationships, dose adaptation 
based on therapeutic drug monitoring (TDM) may optimize 
treatment of pediatric patients treated with anticancer KIs. In 
fact, TDM to improve pediatric treatment outcomes has proven 
its value in nononcology diseases like posttransplantation and in 
infectious diseases.11,12
Practical recommendations for TDM of KIs in the adult setting 
have been proposed and proven beneficial for several anticancer 
drugs and indications.13–15 Despite this existing knowledge, TDM 
is still only sparsely applied, particularly in pediatric oncology. 
The majority of KIs that are being investigated for the treatment 
of pediatric malignancies are currently still in early stages of devel-
opment. Consequently, quantitative exposure–response and expo-
sure–toxicity relationships have not yet been established for these 
drugs in relation to pediatric indications. Therefore, the aim of 
this review is to elaborate on the current knowledge on exposure–
response relationships of KIs in pediatric oncology, and if expo-
sure–response relationships are lacking to summarize the available 
clinical exposure and response data in pediatric and adult patients. 
The ultimate goal is to evaluate the available information in order 
to propose empirical and practical targets, to guide TDM of KIs in 
pediatric oncology.
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DETERMINATION OF TDM TARGETS IN PEDIATRIC 
MALIGNANCIES
The literature was searched for pediatric PK data on KIs for 
which adult thresholds have previously been proposed. PubMed 
searches were performed using the following search terms: 
(((((((((pediatric[Title/Abstract]) OR pediatrics[Title/Abstract]) 
OR paediatric[Title/Abstract]) OR paediatrics[Title/Abstract]) 
OR pediatric patient[Title/Abstract]) OR paediatric patient[Ti-
tle/Abstract]) OR child[Title/Abstract]) OR children[Title/
Abstract])) AND (imatinib OR glivec) for afatinib, alectinib, 
axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, crizo-
tinib, dabrafenib, dasatinib, erlotinib, everolimus, gefitinib, 
ibrutinib, idelalisib, imatinib, lapatinib, lenvatinib, nilotinib, 
nintedanib, osimertinib, palbociclib, pazopanib, ponatinib, re-
gorafenib, sorafenib, sunitinib, trametinib, vandetanib and ve-
murafenib. Additionally, the FDA Clinical Pharmacology and 
Biopharmaceutics Review and the Committee for Medicinal 
Products for Human Use European Public Assessment Report 
were reviewed for pediatric data.
Determination of a target was performed in a stepwise man-
ner as described in Figure 1. A practical PK target was defined as 
the minimally required drug exposure for efficacy, which is feasi-
ble to measure or to extrapolate in clinical practice for the pedi-
atric population. When a pharmacokinetic–pharmacodynamic 
(PK–PD) relationship in pediatric patients has been described in 
literature, the corresponding cutoff minimum plasma drug concen-
tration at the end of a dosing interval (Cmin) that was related to 
improved efficacy was proposed to guide pediatric TDM (level A 
in Figure 1). When such a relationship was not available but the 
target and the disease pathophysiology was deemed similar com-
pared with adults, the adult target that was previously proposed 
was used (level B).13 When an exposure–response relationship in 
adults was not available but the disease pathophysiology was con-
sidered similar in adult and pediatric patients, the average exposure 
in adults that corresponds to the therapeutic dose was proposed 
as an exploratory target to guide pediatric dosing (level C). When 
the molecular target was similar in adult and pediatric patients but 
the pathophysiology of the disease was different (level D), the pro-
posed adult target (either derived from an exposure–response re-
lationship or the average exposure at the approved dose) was used. 
Furthermore, if in this case pediatric PK data were available, the 
average exposure in pediatric patients was proposed as an explor-
atory target (both levels D and E).
PRACTICAL RECOMMENDATIONS FOR TDM OF KIS IN 
PEDIATRIC MALIGNANCIES
Based on the identified literature, recommendations for pediatric 
targets were defined. Table 1 provides an overview of the included 
drugs, the previously published targets in adults, and the proposed 
targets in pediatric patients.
ANAPLASTIC LYMPHOMA KINASE INHIBITORS
The anaplastic lymphoma kinase (ALK) gene has initially been 
identified as the fusion gene in anaplastic large cell non-Hod-
gkin’s lymphoma (ALCL), which accounts for 10–15% of all 
childhood lymphomas. ALK fusions have also been identified 
in pediatric inflammatory myofibroblastic tumors and infant 
high grade gliomas. Activating kinase domain mutations or 
gene amplifications of the full-length ALK receptor have been 
identified in 8% of neuroblastoma patients.16 In adult non-
small cell lung cancer (NSCLC), translocations in ALK have 
been identified as a key driver in the malignant process. It has 
been shown that the inhibition of mutant ALK is more com-
plex compared with translocated ALK in NSCLC. Based on the 
variability in underlying molecular changes in the ALK gene 
and based on the variability in response in NSCLC, the biol-
ogy of ALK in pediatric cancer patients may differ from that 
in adults. Hence, sensitivity to treatment with ALK inhibitors 
Figure 1 Framework to guide TDM in pediatric oncology. TDM, therapeutic drug monitoring.
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may also differ between pediatric patients and adults.16,17 We 
here describe ALK inhibitors for which target Cmin values in 
adults have been proposed.
Crizotinib
In a study investigating crizotinib for the treatment of pediatric re-
lapsed/refractory ALK-positive ALCL, an objective response rate 
(ORR) of 90% was observed (n = 26, age range 3.7–20.8 years old).17 
At the maximum tolerated dose (280 mg/m2 b.i.d.), the mean Cmin 
in pediatric patients was 480 ng/mL, corresponding to a free drug 
concentration of 50 ng/mL.18 The unbound drug concentration of 
50 ng/mL exceeds the concentration of drug producing 50% inhibi-
tion of 10 ng/mL of crizotinib in ALCL cell lines. No relationships 
between exposure and efficacy have been established for crizo-
tinib in adults with NSCLC nor pediatric patients with ALCL.13 
Therefore, the best estimate for a minimum target for efficacy 
Table 1 Proposed TDM targets for KIs in pediatric oncology
  Pediatric Adult
ReferencesDrug
Molecular 
target
Proposed target 
(ng/mL)
Level of 
evidencea 
Proposed target  
(ng/mL)a 
Mean/median 
 exposure (ng/mL)
Outcome parameter 
associated with TDM 
target
Alectinib ALK Cmin ≥ 435 D Cmin ≥ 435 Cmin = 572 Increased ORR
13
Ceritinib ALK Cmin ≥ 871 D Cmin ≥ 871 Cmin = 871 Observed exposure
13
Crizotinib ALK Cmin ≥ 480 E Cmin ≥ 235 Cmin = 274 Increased PFS
17
Bosutinib Brc-Abl Cmin ≥ 147 B Cmin ≥ 147 Cmin = 147 Observed exposure
13
Dasatinib Bcr-Abl Cmin ≥ 2.61 B Cmin ≥ 2.61 Cmin = 2.61 Observed exposure
13
Imatinib Bcr-Abl Cmin ≥ 1000 (CML)
Cmin ≥ 1100 (GIST)
B Cmin ≥ 1000 (CML)
Cmin ≥ 1100 (GIST)
Cmin = 1170 (CML)
Cmin = 1193 (GIST)
Improved MMR, CCYR 13
Nilotinib Bcr-Abl Cmin ≥ 469 B Cmin ≥ 469 Cmin = 1165 Prolonged TTP
13
Ponatinib Bcr-Abl Cmin ≥ 22.8 E Cmin ≥ 34.2 Cmin = 34.2 Observed exposure
37,38
Afatinib EGFR Cmin ≥ 14.4 D Cmin ≥ 14.4 Cmin = 14.4 Observed exposure
13
Erlotinib EGFR Cmin> 500 D Cmin> 500 Cmin = 1010 Observed exposure
13
Gefitinib EGFR Cmin ≥ 200 D Cmin ≥ 200 Cmin = 291 Increased OS
13
Lapatinib EGFR Cmin ≥ 780 E Cmin ≥ 780 Cmin = 780 Observed exposure
13
Osimertinib EGFR Cmin ≥ 166 E Cmin ≥ 166 Cmin = 166 Observed exposure
13
Axitinib VEGFR Cmin> 5 D Cmin> 5 Cmin ≥ 5 Increased OS
13
Cabozantinib VEGFR Cmin ≥ 1125 C Cmin ≥ 1125 Cmin = 1380 Observed exposure
13
Lenvatinib VEGFR Cmin ≥ 51.5 C Cmin ≥ 51.5 Cmin = 51.5 Observed exposure
13
Nintedanib VEGFR Cmin ≥ 13.1 C Cmin ≥ 13.1 Cmin = 13.1 Observed exposure
13
Pazopanib VEGFR Cmin ≥ 20000 B Cmin ≥ 20000 Cmin = 24000 Increased PFS
13
Regorafenib VEGFR Cmin ≥ 1400 C Cmin ≥ 1400 Cmin = 1400 Observed exposure
13
Sorafenib VEGFR Cmin> 3890 C Cmin> 3750 Cmin = 3750 Observed exposure
67
Sunitiniba VEGFR Cmin ≥ 50 (4-2) B Cmin ≥ 50 (4-2) Cmin = 51.6 Increased OS
13
Vandetanib VEGFR Cmin ≥ 730 C Cmin ≥ 795 Cmin = 795 Observed exposure
75,76
Dabrafeniba BRAF Cmin ≥ 99.6 E Cmin ≥ 99.6 Cmin = 99.6 Observed exposure
13
Vemurafenib BRAF Cmin> 42000 B Cmin> 42000 Cmin = 39000 Increased PFS
13
Cobimetinib BRAF Cmin ≥ 127 E Cmin ≥ 127 Cmin = 127 Observed exposure
13
Trametinib BRAF Cmin ≥ 10.6 D Cmin ≥ 10.6 Cmin = 12.1 Increased PFS
13
Everolimus mTOR Cmin ≥ 10.0 B Cmin ≥ 10.0 Cmin = 13.2 Increased PFS
13
Ibrutinib Btk Cmin ≥ 680 E Cmin ≥ 680 Cmin = 680 Observed exposure
13
Idelalisib PI3Kδ Cmin ≥ 318 E Cmin ≥ 318 Cmin = 318 Observed exposure
13
Palbociclib CDK4/6 Cmin ≥ 61 E Cmin ≥ 61 Cmin = 61 Observed exposure
13
ALK, anaplastic lymphoma kinase; Bcr-Abl, breakpoint cluster region-abelson; BRAF, serine/threonine-protein kinase B-raf; Btk, Bruton’s tyrosine kinase; CCYR, 
complete cytogenetic response; CDK4/6, cyclin-dependent kinases 4 and 6; Cmin, minimum plasma drug concentration at the end of a dosing interval; CML, 
chronic myeloid leukemia; EGFR, epidermal growth factor receptor; GIST, gastrointestinal stromal tumor; KIs, small molecule kinase inhibitors; MMR, major 
molecular response; mTOR, mammalian target of rapamycin; PFS, progression free survival; PI3Kδ, phosphatidylinositide 3-kinase; ORR, objective response rate; 
OS, overall survival; TDM, therapeutic drug monitoring; TTP, time to progression; VEGFR, vascular endothelial growth factor receptor.
a(A) Pediatric exposure–response demonstrated; (B) Adult exposure–response in similar disease pathophysiology; (C) No adult exposure–response in 
similar disease pathophysiology; (D) Adult exposure–response in different disease pathophysiology; (E) No adult exposure–response in different disease 
pathophysiology. b[13]. cSum of sunitinib & N-desethylsunitinib. dSum of dabrafenib & hydroxyl-dabrafenib.
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would be the mean pediatric Cmin of 480 ng/mL. Further research 
is, however, needed to confirm this preliminary recommendation.
Ceritinib
A phase I study with ceritinib in pediatric patients with ALCL, 
inflammatory myofibroblastic tumor, rhabdomyosarcoma, or 
neuroblastoma (n = 22, age range 2–17 years old) reported simi-
lar area under the concentration-time curve (AUC) and apparent 
total clearance as in adults at the recommended dose for expansion 
(510 mg/m2 q.d.). Detailed results on exposure (AUC) and clear-
ance were not reported.19 In adults with ALK positive NSCLC, 
only a trend towards higher ORR with higher Cmin could be iden-
tified.20 Thus, the mean Cmin ≥ 871 ng/mL that was reported in 
adults may provide preliminary guidance for individualized dos-
ing in pediatric patients, until further information regarding the 
pediatric application is available.
Alectinib
There are no clinical studies available in which alectinib has 
been used in the treatment of pediatric malignancies. In adults 
with ALK positive NSCLC, a steady-state Cmin  ≥  435  ng/
mL has been proposed as a target to guide TDM of alectinib. 
Patients with a steady-state Cmin above this target showed a 
larger reduction in tumor size compared with patients with a 
steady-state Cmin below 435 ng/mL.
21 As described above, the 
biology of ALK may be different in pediatric malignancies. 
Extrapolation of exposure–response relationships from adults 
with NSCLC to children with other forms of malignancies may 
therefore not be appropriate. In addition, the Cmin in pediat-
ric patients was unavailable. Thus, no specific threshold can be 
proposed at this time.
BREAK POINT CLUSTER REGION – ABELSON ONCOPROTEIN 
INHIBITORS
CML represents 2–3% of pediatric leukemias, with increasing in-
cidence with age. Ph+ CML patients are treated with break point 
cluster region – Abelson (Bcr-Abl) inhibitors. Studies have shown 
that CML biology is slightly different in pediatric and adult dis-
ease.22 A clear explanation for the difference in disease response 
has however not yet been found. Therefore, established expo-
sure–response relationships for Bcr-Abl inhibitors in adults can 
be extrapolated to children with some caution.23 Efforts should 
be made to identify exposure–response relationships in pediatric 
disease.
Imatinib
Several clinical studies in pediatric patients with CML have 
shown that the PK of imatinib and its active metabolite 
(CGP74588) in children and adults are similar when children 
are treated with a body surface area (BSA)-based equivalent 
dose (260 mg/m2 q.d.). Two population PK analyses identified 
body weight as a significant covariate on imatinib clearance. 
The inclusion of age did not improve the model and was thus 
not included.24,25 Additionally, steady-state plasma concentra-
tions in children with solid tumors were similar to the steady-
state plasma concentrations in children and adults with CML 
following body weight–based dosing.26 Nevertheless, informa-
tion on the PK of imatinib during the first 2 years of age is lack-
ing. Multiple trials in adults confirmed that the target Cmin of 
≥1000 ng/mL is associated with a better treatment outcome.13 
Until data on the pediatric exposure–response become avail-
able, we recommend the well-established exposure–response 
based adult target Cmin ≥ 1000 ng/mL as a minimum target for 
dose individualization in children with CML.
Alongside its use in CML, imatinib has also been used to treat 
pediatric gastrointestinal stromal tumors (GIST). For this indi-
cation, imatinib is targeted against the stem cell receptor (KIT) 
and platelet-derived growth factor receptor (PDGFR).27 It has 
been shown that pediatric GIST has a different pathophysiology 
and presentation than adult GIST. Genetic mutations in KIT or 
PDGFR are rare in pediatric patients, and tumors are more often 
located in the stomach.28 Adult studies showed a significant in-
crease in progression-free-survival (PFS) with increased Cmin.
29 
As it has been shown that the PK in pediatric and adult patients 
was similar in patients with CML and in patients with solid tu-
mors, we propose the adult PK target of Cmin ≥ 1100 ng/mL for 
dose individualization in pediatric GIST as an exploratory target.
Dasatinib
A large phase II trial with dasatinib in chronic phase CML showed 
similar to or higher efficacy of dasatinib in pediatric patients com-
pared with historically observed efficacy in adults (n  =  60, age 
range 1.5–27.6 years old). Children were treated with a BSA-based 
dose (60 mg/m2 q.d.) that was equivalent to the approved adult 
flat dose.30 In a phase I study, the dasatinib AUC0-last in pediatric 
patients (n = 58, age range < 2 years–18 years old) treated with a 
BSA-based dose has been reported to be similar to the exposure 
that has been observed in adults; the AUC in adults was, however, 
not reported.31 An exposure–response relationship in pediatric 
patients has not been established as far as we know. In a popu-
lation PK–PD analysis of the adult clinical trials with dasatinib, 
the weighted average steady-state concentration has been related 
to major cytogenetic response (2.11-fold increase of the odds of 
response for every doubling of the average steady-state concentra-
tion).32 Given the clear exposure–efficacy relationship in adults 
and similarity in PK between adult and pediatric patients, using 
the geometric mean Cmin of 2.61  ng/mL that was observed in 
adults seems justified as a minimum TDM target for pediatric 
patients.
Nilotinib
The PK of nilotinib has been investigated in pediatric pa-
tients with Ph+ CML or acute lymphoblastic leukemia (ALL) 
(n  =  15). Here it has been shown that Cmin achieved with 
BSA-based dosing (230  mg/m2 b.i.d.) was slightly lower in 
both children aged 1– <10  years old (mean Cmin 804.8  ng/
mL) and children aged 10– <18 years old (mean Cmin 1073 ng/
mL) compared with adults (mean Cmin 1165 ng/mL).
33 Several 
exposure–response relationships have been established by 
population PK–PD analyses of adult patient data; however, in-
formation on this relationship in pediatric patients is still lack-
ing. Most importantly, a significantly longer time to complete 
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cytogenetic response or major molecular response and short 
time to progression have been identified for adult patients in 
the lowest Cmin quartile compared with the higher quartiles. 
The lowest quartile threshold Cmin was 469  ng/mL for these 
analyses.34 Considering the strong exposure–efficacy relation-
ship in adults, a Cmin ≥ 469 ng/mL is recommended for TDM 
of nilotinib in pediatric patients.
Bosutinib
The first phase I/II study of bosutinib in pediatric patients with 
CML is currently ongoing (European Union Drug Regulating 
Authorities Clinical Trials Database (EudraCT) no. 2015-
002916-34). In adults with CML, associations between PK and 
complete cytogenetic response, complete hematological response, 
and major molecular response have been shown. Additionally, in 
the pivotal adult CML trial, the Cmin was reported to be higher in 
responders than in nonresponders.35 We recommend the median 
adult Cmin of 147 ng/mL as a minimum threshold for TDM in 
pediatric patients with CML, while awaiting the results of clinical 
trial in pediatric patients.
Ponatinib
Preclinical studies have shown that a ponatinib concentration 
of 40 nM suppressed the emergence of any single mutation.36 In 
adults, a statistically significant relationship between dose inten-
sity and probability of major cytogenetic responses in patients 
with CML has been described. It has additionally been shown that 
toxicity was dose dependent. The use of ponatinib in pediatric 
patients is still rare. Hence, pediatric PK and exposure–response 
data are not available.37 Case reports suggested that ponatinib 
treatment is effective in children with Ph+  ALL or CML.38,39 
Based on the relationship between daily dose and toxicity that has 
been described in adults, the dose was lowered in the described 
pediatric cases. With this dose (15 mg q.d.), the serum concentra-
tion of ponatinib was 18.3 ng/mL at 9 hours after dose at the last 
treatment day, which is slightly below the reported active concen-
tration (40  nM; 22.8  ng/mL). Given the very limited evidence 
available, no specific target can be proposed for ponatinib.
EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS
The amplification of epidermal growth factor receptor (EGFR) has 
been observed in 5–10% of pediatric high-grade gliomas (HGGs), and 
overexpression of EGFR is seen in over 80% of pediatric malignant gli-
omas. Pediatric HGGs are regarded as genetically different and more 
malignant tumors than adult brain tumors.40–44 In adults, EGFR 
inhibitors are predominantly applied in EGFR mutated NSCLC. 
Analogy between NSCLC and brain tumors has not yet been demon-
strated. Moreover, penetration of EGFR inhibitors in brain tumors 
may be limited by the blood-brain barrier, and, therefore, higher 
plasma concentrations may be needed for adequate target inhibition. 
It is therefore challenging to extrapolate the pediatric target Cmin from 
adults to children with various brain tumors.
Gefitinib
The exposure of gefitinib in pediatric patients (n = 17, age range 
1.8–21.2  years old) with solid tumors has been shown to be 
consistent with prior knowledge in adults.42 Gefitinib apparent 
clearance was 13.7  ±  6.6 L/hour/m2 in children younger than 
12 years (n = 10) and 14.4 ± 6.9 L/hour/m2 in children older than 
12  years (n  =  7). In addition, median steady-state AUC0-24h es-
timates were similar in pediatric patients compared with adults. 
These findings have been confirmed in a PK analysis of 19 pedi-
atric patients with newly diagnosed brainstem glioma (BSG). In 
an additional exploratory analysis, no evidence of a relationship 
between gefitinib PK and toxicity or efficacy has been identified. 
Moreover, the AUC0-24h achieved in children dosed 250 mg/m
2/
day (11800 ng/mL*hour, n = 6) were comparable with the AUC0-
24h that was associated with antitumor activity in adults with 
solid tumors (8596 ng/mL*hour, n = 7).41,45 In a study with adult 
NSCLC patients, a Cmin ≥ 200 ng/mL has been associated with a 
significantly higher overall survival (4.7 months vs. 14.6 months, 
P = 0.007).13,46 Given the clear exposure–efficacy relationship in 
adults with NSCLC and absence of sufficient pediatric PK data 
and data on target inhibition in pediatric solid tumors and BSG, a 
preliminary Cmin ≥ 200 ng/mL may provide guidance for dosing 
in pediatric patients.
Erlotinib
In population PK–PD analyses including adults with head and 
neck carcinoma (n  =  42) and pediatric patients (n  =  46, age 
range 2–19  years old) with malignant brain tumors, a signifi-
cantly higher elimination capacity in children was identified 
(P < 0.0001) compared with adults.47,48 Typical clearance val-
ues of 0.146 L/hour/kg and 0.095 L/hour/kg have been found 
for children and adults, respectively, resulting in a higher rec-
ommended dose in children (125 vs. 90 mg/m2 q.d. in adults). 
As a result of heterogeneity in disease status between patients 
at time of enrollment, a relationship between exposure and re-
sponse could not be established.49 In the pediatric population, 
only AUC values have been reported but TDM based on AUC 
is difficult to implement. Until new data is available on the PK 
and brain penetration of erlotinib in pediatric patients with ma-
lignant brain tumors, the target that was proposed in adults, 
i.e., Cmin > 500 ng/mL, could be used as a preliminary starting 
point for pediatric dose individualization.13
Lapatinib
Since the human epidermal growth factor receptor 2 (HER2) has 
been shown to play an important role in the pathophysiology of 
pediatric ependymomas, medulloblastomas, and BSG, lapatinib 
has been investigated in children with these malignancies. In these 
clinical trials, lapatinib was administered in a twice-daily dose. It 
is therefore not possible to compare PK data in children to those 
obtained in adults. The pediatric Cmin (data not reported) was re-
ported to be similar to the limited data that were obtained from 
adults treated with twice-daily lapatinib.50,51 The proposed adult 
TDM target of Cmin ≥ 780 ng/mL has been based on the mean 
adult steady-state Cmin at the standard dose (1500 mg q.d.), and 
is therefore not appropriate as a target for pediatric TDM. Future 
studies should focus on exposure–response and exposure–toxic-
ity relationships in pediatric brain tumors, in order to establish a 
valid target for lapatinib TDM in pediatric diseases.
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Afatinib
Afatinib is currently under investigation for the treatment of pediat-
ric patients with HGG, diffuse intrinsic pontine glioma, low grade 
astrocytoma, medulloblastoma, ependymoma, neuroblastoma, rhab-
domyosarcoma, and tumors with known ErbB pathway deregulation 
(NCT-02372006).52 A relationship between exposure and response 
has not yet been reported for afatinib in both pediatric and adult 
patients. However, it has been found that the Cmin in adults experi-
encing Grade 3 diarrhea was higher than those experiencing Grade 
1–2 diarrhea (35.8 vs. 25.2–31.6  ng/mL).53 Considering the very 
limited available data on the PK and brain penetration of afatinib 
in pediatric patients, extrapolation from data obtained from adults 
with NSCLC may be inappropriate. It could be considered to use the 
mean steady-state Cmin found in adult patients, i.e., 14.4 ng/mL, as 
an exploratory minimum target for pediatric TDM.13
Osimertinib
To date osimertinib has not been investigated in pediatric malig-
nancies. Nevertheless, osimertinib might be introduced in pedi-
atric patients as it has been shown that EGFR mutations play a 
role in pediatric malignant brain tumors. An exposure–response 
analysis is lacking in the adult setting. In the absence of an expo-
sure–response target, no appropriate target can be proposed. The 
geometric mean Cmin of the approved 80  mg q.d. daily dose of 
166 ng/mL could for now be used as a reference to guide future 
individual pediatric dosing.13
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR
Vascular endothelial growth factor receptor (VEGFR) inhibitors are 
currently used in the treatment of adults with soft-tissue sarcomas 
(STSs) and renal cell, hepatocellular, and papillary thyroid carci-
noma. Renal cell carcinoma (RCC) in children is rare and is different 
from adult RCC. Different genetic profiles and clinical behavior has 
been observed in pediatric patients.54 Hepatocellular and papillary 
thyroid carcinoma are rare in the pediatric population; similarity in 
pathophysiology is therefore not clarified yet for these cancer types. 
However, it has been shown that VEGFR is overexpressed or plays 
a biological role in Wilms tumors, hepatocellular carcinoma, hepa-
toblastoma, (non)rhabdomyosarcoma, STS, Ewing sarcoma, osteo-
sarcoma, and neuroblastoma.55 Additionally, promising results have 
been reported from several small clinical trials treating pediatric pa-
tients with VEGFR inhibitors.
Axitinib
A phase I trial investigating axitinib in pediatric patients with 
solid tumors has recently been published (n  =  18, age range 
5–17  years old). Pediatric patients were treated with a BSA-
based dose that was equivalent to the adult f lat dose. Toxicity 
and exposure were found to be similar to adults with RCC. 
However, an association between steady-state Cmax or AUC0-last 
and efficacy could not be established.55 In adults, a practical tar-
get Cmin of 5 ng/mL has been proposed based on a small study 
that found a relationship between axitinib Cmin > 5 ng/mL and 
tumor response.56 Considering the limited data in pediatric pa-
tients, the adult cutoff might serve as a preliminary starting 
point for pediatric dose individualization. The relationship 
between this target and efficacy in pediatric patients should, 
however, be assessed, given the differences in biology and patho-
physiology of RCC in pediatric and adult patients.
Cabozantinib
Cabozantinib has been investigated at various dose levels in chil-
dren with recurrent or refractory solid tumors in a phase I trial 
(n  =  41, age range 4–18  years old). No biomarker changes were 
observed across dose levels or among responding patients. The 
recommended phase II dose (RP2D) was 40 mg/m2 q.d., which 
is equivalent to the 60  mg q.d. adult dose that is registered for 
RCC. The PK and toxicity profiles at the RP2D (40 mg/m2 q.d.) 
were similar to that observed in adults with RCC.57 The apparent 
clearance in pediatric patients was 1.1–1.8 L/hour/m2 compared 
with 1.3–2 L/hour/m2 in healthy adults.58 In a case report, two 
children with clear cell RCC were treated with cabozantinib on 
the RP2D. Disease control was shown for over 15 months, which 
was twice the median PFS observed in an adult phase II trial of 
cabozantinib in RCC.59 While no exposure–response relation-
ship has been established for either adult or pediatric patients, a 
specific minimum target cannot be proposed for cabozantinib. 
We recommend to use the mean Cmin of 1125  ng/mL that was 
observed in adults with clear cell RCC as an exploratory guide to 
individualize dosing in pediatric patients.13
Lenvatinib
Several phase I/II studies with lenvatinib in the pediatric set-
ting are currently ongoing. A case report described three patients 
with papillary thyroid carcinoma who were successfully treated 
with lenvatinib.60 Two out of three patients remained stable for 
11 months after start of lenvatinib. A model-based analysis of adult 
PK–PD data showed a correlation between lenvatinib AUC0-24h 
and reduction in tumor size, but a threshold to guide TDM was 
not reported.61 Therefore, TDM in pediatric patients could be 
guided by the mean Cmin of 51.5 ng/mL that was proposed as an 
exploratory minimum target in adults.13
Nintedanib
According to literature, nintedanib has not yet been applied in 
the pediatric setting. A decrease in soluble VEGFR levels with 
increasing Cmin was observed in adults in a small phase I study. 
Additionally, higher nintedanib concentrations have been associ-
ated with hepatotoxicity in an exploratory analysis.62 Considering 
the very limited data on nintedanib exposure–response and expo-
sure–toxicity relationships in both pediatric and adult patients, 
the mean adult Cmin of 13.1 ng/mL may be used as an exploratory 
minimum target in pediatric patients.13
Pazopanib
In a phase I study of pazopanib in children (n = 51, age range 3.8–
23.9 years old) with STSs and other refractory solid tumors, a maxi-
mum tolerated dose of 450 mg/m2 q.d. has been determined, which 
is comparable to the adult recommended flat dose of 800 mg q.d. At 
this dose level, the pediatric day 1 AUC0-24h was similar to that in 
adults (377.6 mg/L*hour for children vs. 275.1 mg/L*hour for adults). 
An exposure–response relationship could not be established.63 
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Pazopanib steady-state plasma drug concentration  ≥  17.5  mg/L 
has been suggested as target for optimal in vivo antitumor and an-
tiangiogenic activity in preclinical models.64 In a clinical study in 
adults, a prolonged PFS in patients with Cmin  ≥  20.5  mg/L com-
pared with patients with a Cmin below this target has been shown.
65 
In a prospective clinical study in adults, the safety and feasibility 
of Cmin (≥20 mg/L) guided dosing in adults has successfully been 
demonstrated.66 It has been shown that an equal number of patients 
discontinued treatment due to toxicity in the low Cmin vs. the high 
Cmin group, and only one patient discontinued treatment after a 
dose escalation. Considering the exposure–efficacy and exposure–
toxicity relationships in adults, a Cmin of 20 mg/L seems justified as 
a minimum target for TDM in pediatric patients.
Regorafenib
In an ongoing phase I trial of regorafenib in pediatric patients 
with solid tumors (n = 41, age range 3–17 years old), the toxicity 
profile was similar to adults, with the exception of hematologic 
events. Hematologic toxicity was seen at a higher rate in heav-
ily pretreated pediatric patients than in adults.67 Observed ex-
posure of regorafenib and active metabolites was similar to the 
adult exposure in the therapeutic dose range, although details 
were not yet reported. Furthermore, using a physiology-based 
PK model, the RP2D of 72  mg/m2 was predicted to result in 
100% of adult exposure. An exposure–response relationship has 
not yet been determined in either adult or pediatric patients.13 
Based on the limited available data, the best estimate of a min-
imum target for regorafenib TDM in pediatric patients would 
be the steady-state mean Cmin of 1.4 mg/L that was observed in 
adults.
Sorafenib
Sorafenib PK has been evaluated in phase I and II studies in 
pediatric patients. In a population pharmacokinetic analysis 
based on pooled data from several pediatric clinical trials, the 
median steady-state Cmin for the RP2D (200 mg/m
2 b.i.d.) was 
3.89 mg/L (range 1.39–10.3 mg/L, n = 37)68. The pharmaco-
kinetic findings from this analysis were consistent with the PK 
results from previous pediatric and adult phase I and phase II 
studies.13,69–71 No significant relationship could be identified 
between the change in VEGF or VEGFR2 and Cmin. A solid 
exposure–response relationship has not yet been described. 
Considering the observed concentrations in pediatric patients 
and lacking exposure–response analysis, a Cmin of 3.89  mg/L 
seems justified to be the exploratory minimum target concen-
tration in pediatric patients.
Sunitinib
Sunitinib is metabolized into its active metabolite N-desethylsunitinib 
by cytochrome P450 3A4. For exposure–response analyses and 
TDM the sum of sunitinib and N-desethylsunitinib concentrations 
is generally used. Due to the development of myelosuppression and 
elevated transaminase levels, the RP2D for sunitinib in pediatric 
patients was established at 15 mg/m2 q.d. on a 4-weeks-on/2-weeks-
off schedule, which is lower than the BSA-based adult equivalent 
(28 mg/m2 q.d.). Hence, the exposure obtained in pediatric patients 
was lower than in adults. The total (sunitinib + N-desethylsunitinib) 
steady-state plasma Cmin was 34.9  ng/mL (n  =  11, range 15.6–
90.5 ng/mL) in a phase I trial with pediatric patients with solid tu-
mors and 55.4 ng/mL (n = 20, 22.9–109.7 ng/mL) in a phase II trial 
evaluating sunitinib for the treatment of pediatric high-grade glioma 
or ependymoma.72,73 In a phase I/II study that investigated sunitinib 
in pediatric patients with advanced GIST, a longer median PFS in 
patients with higher Cmin (median PFS 2.6 months in lower expo-
sure group and PFS 9.0 months in higher exposure group, n = 6) was 
found.28 In a case series of pediatric patients with GIST, higher suni-
tinib doses were tolerated compared with the doses used in the clin-
ical trials and toxicity profiles were similar to the ones observed in 
adult patients (treated with a 50 mg q.d. (4 weeks on/2 weeks off) flat 
dose).74 This was attributed to the fact that the children included in 
clinical studies received more intensive therapy prior to entry in the 
clinical study compared with the children that were described in the 
case series. Exposure–response and exposure–toxicity relationships 
have also extensively been studied in adult patients.13,14 Additionally, 
a TDM feasibility trial in cancer patients confirmed that using a 
target of Cmin  ≥  50  ng/mL (sunitinib  +  N-desethylsunitinib) to 
guide dosing was successful and safe.75 We therefore advise to guide 
individual dosing in pediatric patients based on the adult target of 
Cmin ≥ 50 ng/mL (sunitinib + N-desethylsunitinib) when sunitinib 
is administered in the 4-weeks-on/2-weeks-off schedule.
Vandetanib
In children with multiple endocrine neoplasia type 2B associ-
ated medullary thyroid carcinoma, vandetanib was shown to 
be well tolerated and highly effective at a dose of 100  mg/m2 
q.d. (n = 16).76,77 Exposure reached at this dose level was similar 
to adults treated with the registered f lat dose of 300  mg/day. 
Mean steady-state plasma drug concentration was 730  ng/mL 
in pediatrics and 795 ng/mL in adults. As a consequence of the 
small sample size and low frequency of progression of disease 
in the pediatric study, no exposure–response analyses could be 
performed. Also, in adults an exposure–response relationship 
has not yet been published. Therefore, dose escalations could 
be considered for pediatric patients with an exposure below 
730 ng/mL.
SERINE/THREONINE-PROTEIN KINASE B-RAF AND 
MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS
It has extensively been shown that serine/threonine-protein ki-
nase B-raf (BRAF) V600 mutations are important regulators 
of cell proliferation in adult patients with melanoma.78 Similar 
mutations have been observed in adolescents and adults with 
melanoma. But similarity in disease pathophysiology could not 
be concluded as a result of very low enrolment.79 Additionally, 
BRAF V600E mutations have been found in both high-grade and 
low-grade gliomas.80 Given the differences in tumor location, ex-
trapolations from adult melanoma patients to children with brain 
tumors should be performed carefully.
Vemurafenib
The pediatric PK of vemurafenib has only been studied in adoles-
cents aged 12–17 years with BRAF mutation-positive melanoma 
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(n = 6). All patients treated with the adult dose (960 mg b.i.d.) 
had a steady-state Cmin above the adult target Cmin of 42 mg/L. 
In the lower dose level (720 mg b.i.d.), two out of three patients 
had a steady-state Cmin below this target. Since this study was ter-
minated due to extremely low enrollment, an exposure–response 
relationship could not be identified.78 Considering the compara-
ble exposure in adolescents compared with adults and presumably 
similar pathophysiology of melanoma, it seems reasonable to use 
the threshold of Cmin > 42 mg/L for TDM of vemurafenib in pe-
diatric patients.13
Dabrafenib
A phase II trial with dabrafenib in combination with trametinib 
for pediatric V600-positive HGG and low-grade glioma is cur-
rently ongoing. An interim analysis showed that the objective re-
sponse rate in children was 38% (n = 31), including one complete 
response and 11 partial responses. Additionally, 14 patients had 
stable disease.81 As no pediatric PK data was reported, no specific 
threshold can be proposed for dabrafenib. The adult target Cmin 
can, however, serve to guide individual dosing in children. The 
proposed adult target Cmin in melanoma was based on the me-
dian sum of parent dabrafenib and its active hydroxyl metabolite, 
which was Cmin of 99.6 ng/mL.
82
Trametinib
The mitogen-activated protein kinase/extracellular signal-reg-
ulated kinase pathway has been characterized as an important 
pathway in oncogenesis of pilocytic astrocytoma. Only case series 
of patients (n = 6) with pilocytic astrocytomas that were treated 
with trametinib are available. Partial responses were seen with 
a good quality of life; only minor toxicities were observed.80 A 
population analysis on data from adults with melanoma showed 
an increasing proportion of responders with increasing exposure 
to trametinib. This increase showed a plateau at a Cmin of 10 ng/
mL.83 Additionally, in an adult phase II study, it was observed that 
patients with a Cmin above 10.6 ng/mL had longer PFS than pa-
tients below this Cmin. Nevertheless, this relationship was not con-
firmed in phase III trials. Given the absence of reported pediatric 
PK data, the adult target of Cmin ≥ 10.6 ng/mL could be used as a 
preliminary target to individualize pediatric dosing.13
Cobimetinib
A phase I/II clinical trial investigating the safety and PK of cobi-
metinib in pediatric patients with solid tumors is currently ongo-
ing.84 As this is the first clinical trial that investigates cobimetinib 
in pediatric patients and exposure–response data is absent in adult 
patients, no specific target for the pediatric population can be pro-
posed. The adult mean Cmin ≥ 127 ng/mL might be used to guide 
TDM in pediatrics when treated with cobimetinib for melanoma, 
for the time being.13
OTHER KINASE INHIBITORS USED IN ONCOLOGY
Everolimus
Several in vitro and xenograft studies have shown that rhabdomyo-
sarcoma, neuroblastoma, medulloblastoma/primitive neuroecto-
dermal tumors and pediatric glioblastoma cell lines are sensitive 
to mTOR inhibition. TDM of everolimus has proven its value 
in children with non-oncology-related diseases, but a target for 
TDM in oncology has not yet been reported.11,85 In a phase I trial 
with everolimus in pediatric patients with solid tumors (n = 25, 
age range 3–21 years old) it has been shown that the BSA-adjusted 
dose resulted in an exposure (AUCo-inf) similar to the exposure 
observed in adults treated with the registered flat dose of 10 mg 
q.d.86 In addition, it has been shown that the higher dose levels 
of 3–5  mg/m2 q.d., corresponding to an AUC0-inf of ≥200  ng/
mL*hour, were most effective at decreasing AKT phosphoryla-
tion. A meta-analysis of adult everolimus phase II oncology tri-
als (n = 945) showed that a twofold increase in everolimus Cmin 
was associated with improved tumor size reduction. Also, several 
analyses of adult RCC patients that were treated with everolimus 
found trends towards increased PFS for patients with higher Cmin 
values.87 Given the above, the adult threshold of Cmin ≥ 10 ng/
mL, which was based on an exposure–response analysis in adults 
with RCC and endocrine tumors of the pancreas, seems most 
appropriate to serve as exploratory target for pediatric TDM of 
everolimus.13
Ibrutinib
Ibrutinib, a Bruton’s tyrosine kinase inhibitor, is currently being 
investigated for the treatment of pediatric relapsed or refractory 
mature B-cell non-Hodgkin’s lymphoma. Therefore, pediatric PK 
data are not yet available, and a target for TDM should be based 
on knowledge from adult studies. The target that is used for adults 
is an AUC0-24h of 953 ng/mL*hour for mantle cell lymphoma and 
an AUC0-24h of 680 ng/mL*hour for chronic lymphocytic leuke-
mia (no Cmin data reported). However, the implementation of an 
AUC target in clinical practice is practically challenging. Future 
clinical studies should therefore be performed in order to establish 
a well-defined and practical target to guide individual dosing of 
ibrutinib in pediatric patients.
Idelalisib
The use of idelalisib, a phosphatidylinositide 3-kinase inhibitor, 
for the treatment of pediatric patients is very limited. A phase II 
study aimed to include both adults and pediatric patients older 
than 12 years of age with Hodgkin’s lymphoma, as it was expected 
that disease pathophysiology was similar in these two populations. 
However, no pediatric patients were included.88 Only adult PK 
data are therefore available. Adult dose selection was supported 
by the finding that the 90% maximal effective concentration of 
125  ng/mL that was needed for in vitro phosphatidylinositide 
3-kinase inhibition, was reached by the exposure on the approved 
dose.89 The median Cmin at the approved adult dose was 318 ng/
mL, which could be used as exploratory minimum target for 
TDM in pediatric patients.13
Palbociclib
Palbociclib is a cycline-dependent kinase 4/6 inhibitor. To date, 
palbociclib has not yet been used for the treatment of pediatric 
cancers. Nevertheless, a National Cancer Institute–Children’s 
Oncology Group (NCI-COG) Pediatric MATCH (Molecular 
Analysis for Therapy Choice) trial investigating palbociclib in 
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pediatric patients with tumors harboring activating mutations 
in cell cycle genes is ongoing.90 Also, a dose-escalation study with 
palbociclib in pediatric patients with recurrent/refractory solid 
tumors is ongoing. While data on the pediatric PK of palbociclib 
is lacking, individual concentrations could be compared with the 
adult target of Cmin ≥ 61 ng/mL in order to further guide individ-
ual dosing.13
FUTURE PERSPECTIVES
We explored and summarized the evidence for targets to guide 
dosing in the pediatric patient population and proposed TDM 
recommendations for each of the KIs for which a target has been 
proposed in adult oncology. For none of the KIs, statistically sig-
nificant exposure–response or exposure–toxicity relationships 
that provide valid TDM targets for pediatrics have yet been pub-
lished. This is due to the typically small clinical trial sample sizes, 
lack of phase II studies, and inherent hurdles to collect PK data 
in children. Nevertheless, if no differences in disease pathophys-
iology or pharmacological target are expected between pediatrics 
and adults, established adult exposure–response relationships 
could be extrapolated to the pediatric context.
In this review we propose empirical and practical targets for 
KIs that can be used to individualize dosing in pediatric oncology. 
Targets are based on the minimally required exposure for efficacy, 
following the methods of previously published reviews.13–15 These 
values need to be validated; although the molecular target is the 
same in pediatrics and adults, additional factors may play a role in 
the successful treatment of the disease in pediatric patients. The 
role of the driving molecular target in tumor-cell survival may dif-
fer among different cancer types. Additionally, as the tumor site 
may be different, altered drug concentrations at the target site may 
occur, resulting in a changed exposure–response relationship. In 
adults, it has been shown that the TDM targets on average cor-
respond to approximately 80% of the observed mean Cmin. It has, 
therefore, been proposed, while awaiting exposure–response anal-
yses, to use the mean population exposure as a reference target for 
individual exposure in individual patients when an exposure–re-
sponse relationship has not yet been established.13,14 Additionally, 
the algorithm presented here (Figure 1) provides also guidance 
for TDM of KIs in pediatric oncology when applied without 
prior knowledge on pediatric PK or PD. Several case reports have 
reported the administration of body weight-based or BSA-based 
adult equivalent doses to pediatric patients with good clinical 
results. We strongly urge collecting blood samples in all pediat-
ric patients that are treated with molecular targeted KIs and de-
termine drug concentrations, whenever feasible, in order to gain 
more insight in the exposure–response and exposure–toxicity 
relationships.
Exposure–response relationships are to be expected when taking 
the mechanisms of action and clinical pharmacological character-
istics of KIs into account. The few KIs that are currently regis-
tered for treatment of children with cancer are administered in a 
fixed BSA-based dose. We do recognize the superiority of using a 
BSA-scaled dose over body weight-scaled dosing in pediatric pa-
tients. However, this dosing approach originates from the tradi-
tional toxicity-based clinical trial designs that were used to guide 
dose-finding of conventional, mostly intravenously administered, 
cytotoxic agents. In the currently ongoing clinical trials with KIs 
for the treatment of pediatric cancer, this approach is still used. 
As this approach is based on finding the maximum tolerated dose 
rather than targeting a clinically effective concentration, a risk of 
overdosing might be introduced, which might hamper the deter-
mination of strong exposure–response relationships. However, 
pediatric clinical trials with innovative designs are emerging to 
accelerate the drug development in children and increase the avail-
ability of drugs for children. For instance, in a phase I study inves-
tigating bosutinib in children with CML, dose-finding is based on 
identifying a dose resulting in a mean exposure similar to the mean 
exposure that was found in adults.91
It is well known that PK can differ between children and adults 
and may also vary among children of different ages. Drug distribu-
tion to various compartments of the body may differ in children 
since the proportion of body water and fat is age dependent. In ad-
dition, the quantity of total plasma proteins is reduced in neonates 
and young children, which in turn may result in alterations in drug 
plasma concentrations. Moreover, the metabolism and elimination 
of drug is influenced by maturational processes. Renal elimination 
is fully mature at around one year of age, and the maturation of the 
activity of metabolic enzymes and drug transporters in the GI tract, 
liver, and brain is complex and still not fully characterized.10 Given 
these maturational changes and the high between-patient variability 
in exposure of KIs, individualization of dosing of KIs in pediatric on-
cology may be of great value in order to increase efficacy while reg-
ulating toxicity. In addition, administration issues in children, lack 
of adequate drug formulations, or extemporaneously compounded 
formulations will influence exposure, supporting the need for TDM.
The tolerability of molecular targeted anticancer agents in 
pediatric patients is mostly similar to adults. In 75% of the in-
vestigated molecular targeted agents, the pediatric RP2D was 90–
130% of the BSA-adjusted adult dose. Additionally, available PK 
parameters for these drugs were similar to those in adults.92 This 
advocates for a treatment strategy in which the dose is increased 
on an individual basis until the adult target concentration is 
reached. It should, however, be noted that decreased plasma pro-
tein concentrations in pediatric patients might theoretically result 
in an increase in free drug concentration and thus in a higher risk 
of developing toxicity. However, when dose reductions are re-
quired due to toxicity, TDM can be applied to explore whether 
this toxicity was related to high exposure. The dose could then 
be tapered while maintaining a plasma concentration above the 
target. Hence, this individual patient might still be successfully 
treated at a lower dose. A similar dose reduction strategy involving 
TDM could be considered when high exposure is related to long 
lasting side-effects in pediatrics. To date, such relationships have 
not yet been published. However, it should be noted that long-
term toxicities are seen with molecular targeted agents, such as 
delayed growth and development.93 In pediatric patients treated 
with VEGFR inhibitors, growth plate toxicity has been observed. 
Future research in pediatric  patients is needed to evaluate the 
long-term impact of this toxicity on growth and developmental 
processes, as this information cannot be extrapolated from adult 
study results.93
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In summary, we have described the available pediatric phar-
macokinetics of targeted kinase inhibitors and propose phar-
macokinetic targets in order to guide individualized dosing 
in pediatric cancer patients. For all KIs that were studied, pe-
diatric exposure–response and exposure–toxicity targets are 
lacking. Therefore, most of the described targets are based on 
the exposures that are seen in adult patients. Dose adjustments 
in individual pediatric patients can be based on these targets. 
Nevertheless, these targets should be validated in prospective 
randomized clinical trials in order to show their value in increas-
ing treatment efficacy and decreasing toxicity.
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